News

American Association of Individual Investors6d
Why Arcturus Therapeutics Holdings Inc.’s (ARCT) Stock Is Up 6.84%
Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 6.84%, which has investors questioning if this is right ...
Hosted on MSN16d
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, for active immunization to ...
Arcturus Therapeutics price target lowered to $45 from $71 at Guggenheim
Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $45 from $71 and keeps a Buy rating on ...
Arcturus Gets FDA Fast-Track Designation for Pandemic Influenza A H5N1 Vaccine
Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.
Business Wire5d
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...
Arcturus Therapeutics granted fast track designation for ARCT-2304 from FDA
Arcturus Therapeutics (ARCT) announced that the FDA has granted fast track designation for the self-amplifying mRNA vaccine candidate, ...
Morningstar17d
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 Arcturus Therapeutics Holdings Inc. (the ...
Barron's20d
Arcturus Therapeutics Holdings Inc.
About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...
Seeking Alpha4d
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities ...
Yahoo Finance17d
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
SAN DIEGO, April 10, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development of ...
Barron's21d
Arcturus Therapeutics Holdings Inc.
About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities ...